364 related articles for article (PubMed ID: 26864072)
1. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.
Pavel AB; Sonkin D; Reddy A
BMC Syst Biol; 2016 Feb; 10():16. PubMed ID: 26864072
[TBL] [Abstract][Full Text] [Related]
2. Integrating mutation and gene expression cross-sectional data to infer cancer progression.
Fleck JL; Pavel AB; Cassandras CG
BMC Syst Biol; 2016 Jan; 10():12. PubMed ID: 26810975
[TBL] [Abstract][Full Text] [Related]
3. The Integrative Method Based on the Module-Network for Identifying Driver Genes in Cancer Subtypes.
Lu X; Li X; Liu P; Qian X; Miao Q; Peng S
Molecules; 2018 Jan; 23(2):. PubMed ID: 29364829
[TBL] [Abstract][Full Text] [Related]
4. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
[TBL] [Abstract][Full Text] [Related]
5. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.
Roszik J; Wu CJ; Siroy AE; Lazar AJ; Davies MA; Woodman SE; Kwong LN
Sci Rep; 2016 Jan; 6():19649. PubMed ID: 26787600
[TBL] [Abstract][Full Text] [Related]
6. Integrative Data Analysis of Multi-Platform Cancer Data with a Multimodal Deep Learning Approach.
Liang M; Li Z; Chen T; Zeng J
IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(4):928-37. PubMed ID: 26357333
[TBL] [Abstract][Full Text] [Related]
7. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
9. Adaptive Fuzzy Consensus Clustering Framework for Clustering Analysis of Cancer Data.
Yu Z; Chen H; You J; Liu J; Wong HS; Han G; Li L
IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(4):887-901. PubMed ID: 26357330
[TBL] [Abstract][Full Text] [Related]
10. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
11. Min-redundancy and max-relevance multi-view feature selection for predicting ovarian cancer survival using multi-omics data.
El-Manzalawy Y; Hsieh TY; Shivakumar M; Kim D; Honavar V
BMC Med Genomics; 2018 Sep; 11(Suppl 3):71. PubMed ID: 30255801
[TBL] [Abstract][Full Text] [Related]
12. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
13. A pan-cancer analysis of progression mechanisms and drug sensitivity in cancer cell lines.
Fleck JL; Pavel AB; Cassandras CG
Mol Omics; 2019 Dec; 15(6):399-405. PubMed ID: 31570905
[TBL] [Abstract][Full Text] [Related]
14. ICan: an integrated co-alteration network to identify ovarian cancer-related genes.
Zhou Y; Liu Y; Li K; Zhang R; Qiu F; Zhao N; Xu Y
PLoS One; 2015; 10(3):e0116095. PubMed ID: 25803614
[TBL] [Abstract][Full Text] [Related]
15. Bi-level and Bi-objective p-Median Type Problems for Integrative Clustering: Application to Analysis of Cancer Gene-Expression and Drug-Response Data.
Ushakov AV; Klimentova X; Vasilyev I
IEEE/ACM Trans Comput Biol Bioinform; 2018; 15(1):46-59. PubMed ID: 28650823
[TBL] [Abstract][Full Text] [Related]
16. Identification of constrained cancer driver genes based on mutation timing.
Sakoparnig T; Fried P; Beerenwinkel N
PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
[TBL] [Abstract][Full Text] [Related]
17. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
Covell DG
PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
[TBL] [Abstract][Full Text] [Related]
18. Integrative network-based approach identifies key genetic elements in breast invasive carcinoma.
Hamed M; Spaniol C; Zapp A; Helms V
BMC Genomics; 2015; 16 Suppl 5(Suppl 5):S2. PubMed ID: 26040466
[TBL] [Abstract][Full Text] [Related]
19. IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS.
Ma M; Wang C; Glicksberg BS; Schadt EE; Li SD; Chen R
Pac Symp Biocomput; 2017; 22():473-484. PubMed ID: 27896999
[TBL] [Abstract][Full Text] [Related]
20. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes.
San Lucas FA; Fowler J; Chang K; Kopetz S; Vilar E; Scheet P
Mol Cancer Ther; 2014 Dec; 13(12):3230-40. PubMed ID: 25349306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
